Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Insulin-like peptide 6 (INSL6) is a secreted peptide hormone belonging to the insulin/relaxin protein superfamily, characterized by conserved cysteine motifs and significant similarity to relaxin and relaxin-like factors[1][5][7]. It is encoded by the INSL6 gene, maximally expressed in male germ cells of the testis and proposed to play a role in sperm development and fertilization[3][7]. INSL6 is also upregulated in skeletal muscle following injury, where it functions as a myokine, promoting muscle progenitor cell proliferation, inhibiting apoptosis, and facilitating muscle regeneration[2]. Its biological mechanisms remain largely undetermined, and there are currently no known drugs targeting INSL6 or its signaling pathways. While INSL6 shares structural features with other insulin-like peptides, evidence for its involvement in disease or as a therapeutic target is limited[1][2][3][5][7].
None established
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Insulin-like peptide 6 (INSL6).